Literature DB >> 12774024

Hydrophilic but not hydrophobic bile acids prevent gallbladder muscle dysfunction in acute cholecystitis.

Zuo-Liang Xiao1, Piero Biancani, Martin C Carey, Jose Behar.   

Abstract

The pathogenesis of acute cholecystitis (AC) is controversial. Bile acids may be involved in the pathogenesis of AC because the hydrophobic chenodeoxycholic acid (CDCA) reproduced in vitro the muscle dysfunction observed in AC and was prevented by the hydrophilic ursodeoxycholic acid (UDCA). The present study examined the in vivo effects of UDCA or CDCA on gallbladder muscle dysfunction caused by AC. Guinea pigs were treated with placebo, UDCA, or CDCA for 2 weeks before sham operation or induction of AC by bile duct ligation (BDL) for 3 days. Pretreatment with oral UDCA prevented the defective contraction in response to agonists (acetylcholine [ACh], cholecystokinin 8 [CCK-8], and KCl) that occurs after BDL. Prostaglandin (PG) E(2)-induced contraction remained normal in the placebo and UDCA-treated groups but was impaired in the CDCA-treated group. Treatment with UDCA also prevented the expected increase in the levels of H(2)O(2), lipid peroxidation, and PGE(2) content in the placebo-treated AC group, whereas CDCA caused further increases in these oxidative stress markers. The binding capacity of PGE(2) to its receptors and the activity of catalase were reduced after treatment with CDCA. Treatment with UDCA enriched gallbladder bile acids with its conjugates and reduced the percentage of CDCA conjugates. In contrast, treatment with CDCA significantly decreased the percentage of UDCA in bile. In conclusion, oral treatment with UDCA prevents gallbladder muscle damage caused by BDL, whereas oral treatment with CDCA worsens the defective muscle contractility and the oxidative stress.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12774024     DOI: 10.1053/jhep.2003.50243

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  11 in total

Review 1.  Targets for current pharmacologic therapy in cholesterol gallstone disease.

Authors:  Agostino Di Ciaula; David Q H Wang; Helen H Wang; Leonilde Bonfrate; Piero Portincasa
Journal:  Gastroenterol Clin North Am       Date:  2010-06       Impact factor: 3.806

2.  Disruption of gallbladder smooth muscle function is an early feature in the development of cholesterol gallstone disease.

Authors:  B Lavoie; B Nausch; E A Zane; M R Leonard; O B Balemba; A C Bartoo; R Wilcox; M T Nelson; M C Carey; G M Mawe
Journal:  Neurogastroenterol Motil       Date:  2012-05-24       Impact factor: 3.598

3.  Ursodeoxycholic acid improves muscle contractility and inflammation in symptomatic gallbladders with cholesterol gallstones.

Authors:  Michele Pier Luca Guarino; Ping Cong; Michele Cicala; Rossana Alloni; Simone Carotti; Jose Behar
Journal:  Gut       Date:  2006-12-21       Impact factor: 23.059

4.  Impact of ursodeoxycholic acid on a CCK1R cholesterol-binding site may contribute to its positive effects in digestive function.

Authors:  Aditya J Desai; Maoqing Dong; Kaleeckal G Harikumar; Laurence J Miller
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2015-07-02       Impact factor: 4.052

Review 5.  Smooth muscle function and dysfunction in gallbladder disease.

Authors:  Piero Portincasa; Agostino Di Ciaula; Gerard P vanBerge-Henegouwen
Journal:  Curr Gastroenterol Rep       Date:  2004-04

6.  ATP induces guinea pig gallbladder smooth muscle excitability via the P2Y4 receptor and COX-1 activity.

Authors:  Aaron C Bartoo; Mark T Nelson; Gary M Mawe
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2008-04-24       Impact factor: 4.052

7.  Effects of long term hydrophilic bile acid therapy on in vitro contraction of gallbladder muscle strips in patients with cholesterol gallstones.

Authors:  Mehmet-Refik Mas; Bilgin Comert; Nuket Mas; Levent Yamanel; Haluk Ozotuk; Ilker Tasci; Riadh-P Jazrawi
Journal:  World J Gastroenterol       Date:  2007-08-28       Impact factor: 5.742

8.  Prevention of gallbladder hypomotility via FATP2 inhibition protects from lithogenic diet-induced cholelithiasis.

Authors:  Kevin M Tharp; Amin Khalifeh-Soltani; Hyo Min Park; David A Yurek; Alaric Falcon; Louis Wong; Rouying Feng; Kamran Atabai; Andreas Stahl
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2016-03-31       Impact factor: 4.052

9.  lncRNA-PDPK2P promotes hepatocellular carcinoma progression through the PDK1/AKT/Caspase 3 pathway.

Authors:  Weidong Pan; Wen Li; Jun Zhao; Zhiyi Huang; Jingyuan Zhao; Shuxian Chen; Chusi Wang; Youqiu Xue; Feng Huang; Qiannan Fang; Julie Wang; David Brand; Song Guo Zheng
Journal:  Mol Oncol       Date:  2019-08-22       Impact factor: 6.603

Review 10.  An Update on the Lithogenic Mechanisms of Cholecystokinin a Receptor (CCKAR), an Important Gallstone Gene for Lith13.

Authors:  Helen H Wang; Piero Portincasa; Min Liu; Patrick Tso; David Q-H Wang
Journal:  Genes (Basel)       Date:  2020-11-29       Impact factor: 4.096

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.